BiotechTube

Durvalumab (Imfinzi) + Tremelimumab

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscle-invasive Bladder Cancer

Conditions

Muscle-invasive Bladder Cancer

Trial Timeline

Jul 15, 2018 → May 18, 2020

NCT ID
NCT03234153

About Durvalumab (Imfinzi) + Tremelimumab

Durvalumab (Imfinzi) + Tremelimumab is a phase 2 stage product being developed by AstraZeneca for Muscle-invasive Bladder Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03234153. Target conditions include Muscle-invasive Bladder Cancer.

What happened to similar drugs?

0 of 3 similar drugs in Muscle-invasive Bladder Cancer were approved

Approved (0) Terminated (0) Active (3)
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
🔄AtezolizumabRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03234153Phase 2Terminated

Competing Products

12 competing products in Muscle-invasive Bladder Cancer

See all competitors
ProductCompanyStageHype Score
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
44
Pembrolizumab + GemcitabineMerckPhase 2
39
Chemotherapy + Immunotherapy Induction + Immunotherapy MaintenanceMerckPhase 2
42
Autogene Cevumeran + Nivolumab + SalineRochePhase 2
42
AtezolizumabRochePhase 3
44
Nivolumab + Nab-paclitaxel + NivolumabBristol Myers SquibbPhase 2
31
Cretostimogene GrenadenorepvecCG OncologyPhase 2
39
CG0070 + NivolumabCG OncologyPhase 1
26
AU-011Aura BiosciencesPhase 1
26
REOLYSIN® + Gemcitabine + CisplatinOncolytics BiotechPhase 1
11